Lipid Abnormalities and Oxidized LDL in Chronic Kidney Disease Patients on Hemodialysis and Peritoneal Dialysis

REFERENCES

• Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim R. The elephant in uremia: Oxidant stress as an underlying concept of cardiovascular disease in uremia. Kidney Int. 2002;62:1524–1538.
   PubMed Web of Science ®Google Scholar
• McCullough PA. Why is kidney disease the “spoiler” for cardiovascular outcomes? J Am Coll Cardiol. 2003;41:725–728.
   PubMed Web of Science ®Google Scholar
• Stevinkel P, Alvestrand A. Inflammation in end-stage renal disease: Sources, consequences, and therapy. Semin Dial. 2002;15:329–337.
   PubMed Web of Science ®Google Scholar
• Samouilidou E, Grapsa E. Effect of dialysis on total antioxidant capacity and lipid peroxidation products in patients with end-stage renal failure. Blood Purif. 2003;21:209–212.
   PubMed Web of Science ®Google Scholar
• Shoji T, Ishimura E, Inaba M, Tabata T, Nishizawa Y. Atherogenic lipoproteins in end-stage renal disease. Am J Kidney Dis. 2001;38:S30–S33.
   Web of Science ®Google Scholar
• Kaysen G. Lipid and lipoprotein metabolism in chronic kidney disease. J Ren Nutr. 2009;19:73–77.
   PubMed Web of Science ®Google Scholar
• Liu J, Rosner MH. Lipid abnormalities associated with end-stage renal disease. Semin Dial. 2006;19:32–40.
   PubMed Web of Science ®Google Scholar
• Witzum JL. Role of oxidized low-density lipoprotein in atherogenesis. Br Heart J. 1993;69:12–13.
   Google Scholar
• Brown MS, Goldstein J. Lipoprotein metabolism in the macrophage. Ann Rev Biochem. 1983;52:223–261.
   PubMed Web of Science ®Google Scholar
• Inoue T, Uchida T, Kamishirado H, Takayanagi K, Morooka S. Antibody against oxidized low density lipoprotein may predict progression or regression of atherosclerotic coronary artery disease. J Am Coll Cardiol. 2001;37:1871–1876.
   PubMed Web of Science ®Google Scholar
• Davidson MH, Toth PP. High-density lipoprotein metabolism: Potential therapeutic targets. Am J Cardiol. 2007;100:n32–n40.
   PubMed Web of Science ®Google Scholar
• Watson AD, Berliner JA. Hama SY, . Protective effect of high-density lipoprotein associated paraoxonase: Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest. 1995;96:2882–2891.
   PubMed Web of Science ®Google Scholar
• Aviram M. Review of human studies on oxidative damage and antioxidant protection related to cardiovascular diseases. Free Radic Res. 2000;33:S85–S97.
   PubMed Web of Science ®Google Scholar
• Moradi H, Pahl M, Elahimehr R, Vaziri N. Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease. Transl Res. 2009;153:77–85.
   PubMed Web of Science ®Google Scholar
• Meier P, Spertini F, Blanc E, Burnier M. Oxidized low density lipoproteins activate CD4+ T cell apoptosis in patients with end-stage renal disease through Fas engagement. Am Soc Nephrol. 2007;18:331–342.
   PubMed Web of Science ®Google Scholar
• Alabakovska S, Todorova B, Labudovic D, . LDL and HDL subclass distribution in patients with end-stage renal diseases. Clin Biochem. 2002;35:211–216.
   PubMed Web of Science ®Google Scholar
• Schiavon R, Battaglia P, De Fanti E, HDL3-related decreased serum paraoxonase (PON) activity in uremic patients: Comparison with PON1 polymorphism. Clin Chim Acta 2002;324:39–44.
   PubMed Web of Science ®Google Scholar
• Gugliucci A, Mehlhaff K, Kinugasa E, Paraoxonase-1 concentrations in end-stage renal disease after hemodialysis: Correlation with low molecular AGE adduct clearance. Clin Chim Acta 2007;377:213–220.
   PubMed Web of Science ®Google Scholar
• Piperi C, Kalofoutis M, Tzivras M, Troupis T, Skenderis A, Kalofoutis A. Effects of hemodialysis on serum lipids and phospholipids of end-stage renal failure patients. Mol Cell Biochem. 2004;265:57–61.
   PubMed Web of Science ®Google Scholar
• Samouilidou E, Karpouza A, Grapsa E, Tzanatou-Exarchou H. Serum oxidized LDL is inversely associated with HDL2-cholesterol subclass in renal-failure patients on hemodialysis. Nephron Clin Pract. 2010;115:c289–c94.
   Google Scholar
• Hirano T, Nohtomi K, Koba S, Muroi A, Ito Y. A simple and precise method for measuring HDL-cholesterol subfractions by a single precipitation followed by homogenous HDL-cholesterol assay. J Lipid Res. 2008;49:1130–1136.
   PubMed Web of Science ®Google Scholar
• Prichard S. Impact of dyslipidemia in end-stage renal disease. J Am Soc Nephrol. 2003;14:S315–S320.
   PubMed Web of Science ®Google Scholar
• Atman P-O, Samuelsson O, Alaupovic P. Lipoprotein metabolism and renal failure. Am J Kidney Dis. 1993;21:573–591.
   PubMed Web of Science ®Google Scholar
• Kronenberg F, Lingenhel A, Neyer U, . Prevalence of dyslipidemic risk factors in hemodialysis and CAPD patients. Kidney Int. 2003;63:S113–S116.
   PubMed Web of Science ®Google Scholar
• Moberly JV, Altman P-O, Samuelsson O, Alterations in lipoprotein composition in peritoneal dialysis patients. Perit Dial Int. 2002;22:220–228.
   PubMed Web of Science ®Google Scholar
• Cheng SC, Chu TS, Huang K, . Association of hypertriglyceridemia and insulin resistance in uremic patients undergoing CAPD. Perit Dial Int. 2001;21:282–289.
   PubMed Web of Science ®Google Scholar
• Prinsen B, Rabelink T, Romijn J, . A broad-based metabolic approach to study VLDL apoB100 metabolism in patients with ESRD and patients treated with peritoneal dialysis. Kidney Int. 2004;65:1064–1075.
   PubMed Web of Science ®Google Scholar
• Samouilidou E, Grapsa E, Kakavas I. Lagouranis, Agrogiannis B. Oxidative stress markers and C-reactive protein in end-stage renal failure patients on dialysis. Int Urol Nephrol. 2003;35:393–397.
   PubMed Web of Science ®Google Scholar
• Göçmen AY, Sahin E, Kocak H, Tuncer M, Gümüslü S. Levels of asymmetric dimethylarginine, nitric oxide and lipid peroxidation markers in patients with end-stage renal disease having peritoneal dialysis treatment. Clin Biochem. 2008;41:836–840.
   PubMed Web of Science ®Google Scholar
• Mekki K, Bouchenak M, Remaoun M, Bellville JL. Effect of long-term hemodialysis on plasma lecithin: Cholesterol-acyltransferase activity and the amounts and compositions of HDL2 and HDL3 in hemodialysis-treated patients with chronic renal failure: A 9-year longitudinal study. Med Sci Monit. 2004;10:CR439–CR446.
   PubMed Web of Science ®Google Scholar
• Bergesio F, Monzani G, Guasparini A, . Cardiovascular risk factors in severe chronic renal failure: The role of dietary treatment. Clin Nephrol. 2005; 64: 103–112.
   PubMed Web of Science ®Google Scholar
• Drüeke T, Wilko-Sarsat V, Massay Z, . Iron-therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 2002;106:2212–2217.
   PubMed Web of Science ®Google Scholar
• Bayés B, Pastor MC, Bonal J, Foraster A, Romero R. Oxidative stress, inflammation and cardiovascular mortality in hemodialysis–role of seniority and intravenous ferrotherapy: Analysis at 4 years of follow-up. Nephrol Dial Transplant 2006;21:984–990.
   PubMed Web of Science ®Google Scholar
• Pawlak K, Pawlak D, Mysliwiec M. Long-term erythropoietin therapy does not affect endothelial markers, coagulation activation and oxidative stress in hemodialysed patients. Thromb Res. 2007;120:797–803.
   PubMed Web of Science ®Google Scholar